Talidomida. Pasado y presente de un fármaco en busca de indicación.

Revisión Bibliográfica.

Bibliografía 

1.       Lenz W. Thalidomide and congenital abnormalities. Lancet 1962; 1: 45.

2.       McBride WG. Thalidomide and congenital abnormalities. Lancet 1961; 4: 1358.

3.       Lenz W. Lessons to be learned from thalidomide. En: Drugs in pregnancy and delivery. Report on the Thirteen European Symposium on Clinical Farmacological Evaluation in Drug Control. Copenhague: WHO Regional Office for Europe, 1984: 45-51.

4.       Taussig HB. A study of the German outbreak of focomelia. JAMA 1962; 180: 1106-14.

5.       Smithells RW, Leck I. The incidence of ear and limb defects since the withdrawal of thalidomide. Lancet 1963; 1: 1095-7.

6.       Laporte JR, Tognoni G. Estudios de Utilización de Medicamentos y de Farmacovigilancia. En: Laporte JR. Principios de epidemiología del medicamento.2da ed. España: Masson-Salvat; 1993. p. 1-24.

7.      Lenz W. Thalidomide: facts and inferences. En: Soda T, ed. Drug-induced sufferings. Amsterdam: Excerpta Médica, 1980: 103-9.

8.       Laporte JR, Capella D. Mecanismos de Producción y diagnóstico clínico de los efectos indeseables producidos por medicamentos. En: Laporte JR. Principios de epidemiología del medicamento.2da ed. España: Masson-Salvat; 1993. p. 95-109.

9.        Peuckmann V, Fish M, Bruera E. Potential novel uses of thalidomide: focus on paliative care. Drugs 2000 Aug; 60 (2): 273-92.

10.   Beto Av, Ferreira MA, Bosco AA, Machado RD, Andrade SP. Differential effects on angiogénesis and tumor growth in mice. Inflammation 2001 Apr, 25 (2): 91-6.

11.   Gutschow M, Hecker T, Thiele A, Hayschild S, Eger K. Aza analogues of thalidomide: syntesis and evaluation as inhibitors of tumor necrosis factor-alfa  production in vitro. Bioorg Med Chem 2001 Apr; 9 (4): 1059-65.

12.     Zhou S, Paxton JW, Kestell P, Tingle MD, Ching ML. In vitro and in vivo kinetic interactions of the antitumor agent 5,6- dimethylxanthenone-4-acetic acid with thalidomide and diclofenac. Cancer Quemother Pharmacol 2001 Apr; 47 (4): 319-26.

13.   Bousvaros A, Muller B. Thalidomide in gastrointestinal disorders. Drugs 2001: 61 (6): 777-87.

14.   Calabrese L, Resztak K. Thalidomide Revisited: Pharmacology and clinical applications.Exp Op Invest Drugs 1998; 7: 2043-60.

15.   Cwynarsky K. Old drugs on new approaches to haematology. Lancet 1998; 352: 1992.

16.   Chambers J. A cybernetic theory of morality end moral autonomy.  Sct Eng Ethics 2001 April, 7 (2): 177-92.

17.   Bland Jm, Jones DR, Bennet S, Cook DG, Haines AP, McFarlane AJ. Is the clinical trial evidence about new drugs statistically adecuate? Br J Cl Pharmac 1985; 19: 155-60.

18.   Marriot JB, Muller G, Dalgleish A. Thalidomide as an emerging inmunotherapic agent. Inmunol Today 1999; 20: 538-40.

19.   D´Amato M, Loughnan M, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogénesis. Proc Nat Academy Sci 1994; 91: 4082-85.

20.   Anderson KC. Advances in desease biology. Therapeutic implications. Semin Hematol 2001 Apr; 38 (2,suppl 3): 6-10.

21.   Teo SK, Scheffler MR, Kook KA, Tracewell WE, Colburn WA, Stirling DI, Thames SD. Thalidomide dose proportionality assessment following single doses to healthy subjets. J Clin Pharmacol 200l Jun;  41, (6): 662-7.

22.   Goldman DA. Thalidomide use: past history end current implications for practice. Oncol Nurs Forum 2001 Apr; 28 (3): 471-7.

23.   Zappasodi P, Lorenzi A, Corso A. Thalidomide in refractory myeloma patiens: early changes in bone marrow cellularity. Haematologica 2001 Apr; 86 (4): 448.

24.   Tosi P, Ronconi S, Zamagni E, Cellini C, Grafone T, Cangini D, et al. Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation. Haematologica 2001 Apr; 80 (4): 409-13.

25.   Kyle RA. Update on the treatment of multiple myeloma. Oncologist 2001: 6 (2): 119-24.

26.   Scoville CD. Pilot study using the combination of methotrexate and thalidomide in the treatment of rheumatoid arthritis. Clin Exp Rheumatol 2001 May-Jun; 19 (3): 360-1.

27.   Kava C, Spraul CW, Zavazava N, Lane GK, Lane GE. Thalidomide and Prednisolone Inhibit Growth Factor-Induced Human Retinal Pigment Epithelium cell proliferation in vitro. Oftalmologica 2001 Jul-Ag; 215 (4): 284-9.

28.   Arora M, Wagner TE, Davies SM, Blazar BR, Detor T, Enright H, et al. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host desease. Biol Blood Marrow Transplant 2001; 7 (5): 265-73.

29.   Kho YH, Pool MO, Jansman FG, Harting IW. Pharmacotherapeutic options  in inflamatory bowel desease: an update. Pharm World Sci 2001 Feb: 23 (1): 17-21.

30.   Facchini S, Candusso M, Martelossi S, Liubich M, Panfili E, Ventura A. Eficacy of long-term treatment with thalidomide  in children and young adults with Crohn desease: preliminary results. J Pediatr Gastroenterol Nutr 2001 Feb; 32 (2): 178-81.

31.   Ginsburg PM, Hanan I, Ehrenpreis ED. Treatment of severe esophageal Crohn´s desease with thalidomide. Am J Gastroenterol 2001 Apr; 96 (4): 1305-6.

32.   Conteas CN, Berlin OG, Ash LR, Pruthi JS: Therapy for human  gastrointestinal microsporidiosis. Am J Trop Med Hyg 2000 Sept-Oct; 63 (3-4): 121-7.

33.   Moraes M, Rosso G. Thalidomide and its dermatologic uses. Am J Med Sci 2001 May; 321(5): 321’6.

34.   Arrese TE, Domínguez-Soto L, Hoijo Tomoka MT, Vega-Menije E, Cortes-Franco R, Guevara E, Pierard GE. Effectors of inflamation in actinic prurigo. J Am Acad Dermatol 2001 Jun; 44 (6): 957-61.

35.   Brik R, Shamali H, Bergman R. Succesful thalidomide treatment of severe infantile behcet desease. Peditr Dermatol 2001 Mar-Abr; 18 (2): 143-5.

36.   Kaklamanis Vg, Kaklamanis PG. Treatment of behcet´s desease- an update. Semin Arthritis Rheum 2001 Apr: 30 (5): 299-312.

37.    Sosa M, Flores G, Estrada S, Orea M, Gomez J. Tratamiento comparativo entre la talidomida y factor de transferencia en dermatitis atópica severa. Revista Alergia México; XLVIII (2): 56-64.

38.   Jessop S, Whitelaw D, Jordan E. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev 2001: 1: CD002454.

39.   Karim MY, Ruiz-Irastorza G, Khamashta MA. Hughes GR. Update on therapy-thalidomide on the treatment of lupus. Lupus 2001:10(3): 188-92.

40.   Ruiz-Irastorza G, Khamashta MA, CastellinoG, Hughes GR. Systemic lupus erytematosus. Lancet 2001 Mar 31:357(9261): 1027-32.

41.   Short SC, Trish D, Dowe A, Hines F, Gore M, Brada M. Thalidomide as an anti angiogenic agent in relapsed gliomas. J Neurooncol 2001 Jan; 51 (1): 41-5.

42.   Mantovani G, Maccio A, Massa E, Madeddu C. Managing cancer- related anorexia-cachexia. Drugs 2001; 61 (4): 499-514.

43.   Govindarajan R, Heaton K, Broadwater JR, Lang NP, Hauer-Jensen M.  Effect of thalidomide on gastrointestinal toxic effects of  irinotecan. Lancet 2000 Aug 12; 356(9229): 566-7.

44.   Günzler V. Thalidomide in human inmunodeficiency virus (HIV) patients: a review of safety considerations. Drug Safety 1992; 7:116-34.

45.   Strauss RS, Das KM. Thalidomide induced sensory neuropathy. J Pediatr Gastroenterol Nutr 2001 Mar; 32 (3): 322-4.

46.   García-Albea E, et al. Jaqueca Típica y Talidomida. Med Clin (Barc) 1993;100:557.

47.   Fox MR, Harris A. Inctractable insomnia after cessation of treatment with thalidomide. Gastroenterology 2001 May; 120 (6): 1567-8.

Año 2002. Universidad Médica de Camagüey. Facultad de Medicina.